Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513019 · ClinicalTrials.gov registry record · Phase 2
Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
A Phase 2 study of Dermatillomania and Neurotic Excoriation, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00513019 is a Phase 2 study of Dermatillomania and Neurotic Excoriation that has completed, run by University of Chicago. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00513019, a Phase 2 study of Dermatillomania and Neurotic Excoriation, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lamictal (lamotrigine)
Study Locations (1)
Minnesota
- Ambulatory Research Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513019
The ClinicalTrials.gov registry entry for NCT00513019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Dermatillomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00513019 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00513019 about?
NCT00513019 is a clinical study titled "Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation". The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested ...
What is the current status of trial NCT00513019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2007-08. Estimated completion is 2009-09.
What conditions does trial NCT00513019 study?
This clinical trial studies the following conditions: Dermatillomania, Neurotic Excoriation, Pathologic Skin Picking, Psychogenic Excoriation.
What interventions are being tested in trial NCT00513019?
The interventions under investigation include: Placebo (DRUG), Lamictal (lamotrigine) (DRUG).
Who is sponsoring clinical trial NCT00513019?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00513019 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatillomania
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.